Prescribing information




A prospective 4-year, multinational, extension study evaluating the long-term safety and efficacy of EXJADE in transfusion-dependent, iron-overloaded patients with SCD.

Trial cohort1

Overall, 185 patients received one dose of EXJADE in the extension study of which 90 patients (48.6%) were aged <16 years.

Key inclusion criteria1

  • Patients with SCD who had completed the 1-year, Phase II, randomised deferoxamine-controlled study
  • Ferritin levels ≥500 μg/L

EXJADE treatment regimen1

  • In the EXJADE cohort, the initial dosage was either maintained or increased by 5 or 10 mg/kg/day depending on patients’ serum ferritin trends in the 1-year core study
  • In the deferoxamine crossover cohort, the recommended initial EXJADE dose was 20 mg/kg/day in patients receiving 2–4 units of pRBC per month*
  • Dose adjustments in increments of 5 or 10 mg/kg per day were allowed every 3 months based on trends in serum ferritin levels and safety parameters


  • The safety and tolerability profile of treated patients from BL to Year 5
  • To evaluate the efficacy of EXJADE in reducing iron burden based on change in serum ferritin levels from BL to Year 5

*A 20 mg/kg/day EXJADE DT dose is equivalent to 14 mg/kg/day EXJADE FCT; a 30 mg/kg/day EXJADE DT dose is equivalent to 21 mg/kg/day EXJADE FCT.2,3

Initial EXJADE doses of 10 or 30 mg/kg/day could be considered for patients with lower or higher transfusion requirements, respectively.


Abbreviations: BL, baseline; DT, dispersible tablets; FCT, film-coated tablets; ICT, iron chelation therapy; pRBC, packed red blood cells; SCD, sickle cell disease.


  1. Vichinsky E, et al. Long-term safety and efficacy of deferasirox (EXJADE®) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease. Br J Haematol 2011;154(3):387–97.
  2. EXJADE® dispersible tablets summary of product characteristics.
  3. EXJADE® film-coated tablets summary of product characteristics.
Rate this content: 
No votes yet
UK | March 2021 | 111826

Ask Speakers


Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at Adverse events should also be reported to Novartis via or online through the pharmacovigilance intake (PVI) tool at
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at